This trial will study the safety and efficacy of intravenous infusion of cultured autologous adult adipose derived mesenchymal stem cells for the treatment of Cerebral Palsy
Studies have shown that stem cell treatment is safe and efficacious for the treatment of Cerebral Palsy (CP). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured autologous adult adipose derived mesenchymal stem cells (AD-MSCs) for the treatment of CP. Patients with CP will receive a single intravenous infusion of AD-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
cultured autologous adult adipose derived mesenchymal stem cells
Mitera Hospital Athens Greece
Marousi, Greece
Safety (adverse events)
Clinical monitoring of possible adverse events or complications
Time frame: Four year follow-up
Efficacy: Gross Motor Function Measure (GMFM)
It will be completed for each follow up point
Time frame: Four year follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.